clinical trial · NCT00879086
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Breast CancerEribulin MesylateIxabepilone
brief summary
The purpose of this study in patients with advanced breast cancer is to compare the incidence and severity of neuropathy adverse events for the two treatment groups (eribulin versus ixabepilone) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) grading.
started
Mar 31, 2009
primary completion
Apr 30, 2013
completion
Apr 30, 2014
last updated
Jun 22, 2023
official title
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol